Ganeden Receives FDA GRAS on Probiotic-Derived Immune Health Ingredient: Staimune

Food and Healthcare Press Releases Thursday June 8, 2017 12:32
CLEVELAND--8 Jun--PRNewswire/InfoQuest
New patented offering expands immunity formulations in functional foods and beverages

Ganeden, already known as a leader in probiotic technology, has used its patented probiotic strain to develop an immune health ingredient: Staimune(TM). The new ingredient utilizes the cells of the probiotic GanedenBC30(R) to support immune health, at cost effective inclusion levels. Available later this summer, Ganeden anticipates Staimune to be an industry-changing development.

Officially identified as "Inactivated Bacillus coagulans GBI-30, 6086", Staimune's ease of formulation opens up new opportunities in functional foods and beverages—most importantly in shelf-stable beverages and high-water-activity products. Staimune is FDA GRAS, non-GMO, organic compliant and kosher, making it extremely accessible for use in a vast amount of applications.

Multiple peer-reviewed and published studies show the immune health benefits of GanedenBC30 cells, with additional in-vitro and human clinical studies on Staimune currently underway.

"After seeing the impressive immune supporting benefits of GanedenBC30, we decided to dive further into the mechanism of action," said Michael Bush, president and CEO of Ganeden. "We discovered and ultimately patented this novel ingredient which provides the opportunity to share the immune benefits of the probiotic in product formats that do not support the use of the live organism."

Staimune provides the option for manufacturers that want to focus specifically on immune health, and for those with processes that cause formulation challenges for live probiotics. With an inclusion rate of just 50mg, Staimune does not alter the flavor or texture profiles of finished goods, allowing for easy application into a large number of product categories.

Staimune will be available for formulation starting in the summer of 2017. For more information on the immune health ingredient and Ganeden's other probiotic technologies, visit GanedenProbiotics.com.
About Ganeden:

Ganeden(R) is at the forefront of probiotic research and product development with an extensive library of published studies and more than 135 patents for probiotic technologies in the supplement, food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30(R) its patented, FDA GRAS and highly stable probiotic ingredient. Through the fermentation process of GanedenBC30, Ganeden developed Bonicel(R), the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. Ganeden's newest ingredient, Staimune(TM) is a patented probiotic technology comprising of inactivated GanedenBC30 cells, which have immune benefits. For more information about Ganeden and licensing opportunities, visit GanedenProbiotics.com.

Logo - https://mma.prnewswire.com/media/458885/Ganeden_Logo.jpg
Logo - https://mma.prnewswire.com/media/520839/Staimune_Logo.jpg

Latest Press Release

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

TIENS Group Launches Global Expansion Into New Retail

Leading healthcare company, TIENS Group, has announced their global expansion into the new retail market with the opening of a new flagship TIENS Experience Store in China. Located in the TIENS International Health Industrial Park, the new store features...

Medicines We Can Trust Campaign Rallies Mekong Governments and Leaders to Improve Access to Quality Medicines

Cambodian Prime Minister Hun Sen and other leaders from the Greater Mekong Subregion joined hands as part of a global campaign to improve access to quality medicines. The announcement was made during the Phnom Penh Regional Conference on the fight...

SI Group Announces New Executive Leadership

SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals and chemical intermediates, announced today the company's new executive leadership team. These changes follow the October 15, 2018...

Grunenthal Acquires Global Rights for Qutenza(R)

Grunenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza(R) (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grunenthal is now...

Related Topics